{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:49:55Z","timestamp":1791557395557,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The EBMT risk score, incorporating five factors to estimate the risks associated with haematopoietic stem cell transplantation (HSCT) in adult patients, has not been validated in children. This study aims to assess this score in 9447 children undergoing allogeneic HSCT for acute lymphoblastic or myeloid leukemia (ALL\/AML) between 2010 and 2021. Risk factors were coded according to the original EBMT score. In both ALL (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20095774) and AML (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20093673), only disease status and the time from diagnosis to HSCT significantly impacted all the outcomes in the multivariable analysis. The combination of female donors and male recipients did not affect overall survival (OS), relapse incidence (RI), non-relapse mortality (NRM), and leukemia-free survival (LFS). Additionally, the prognostic impact of donor type was not evident; when viewed as two modalities, the impact of MSD versus non-MSD on different outcomes in ALL was inconsistent with those observed in AML. Consequently, in both ALL and AML, scores ranging from 3 to 5 significantly affected all outcomes, whereas a score of 2 did not significantly impact NRM or RI in AML. Therefore, this analysis demonstrates that the adult EBMT risk score is not entirely reliable in children with acute leukemia, highlighting the need for a new pediatric-specific prognostic score.\n                  <\/jats:p>","DOI":"10.1038\/s41409-026-02952-8","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:49:24Z","timestamp":1784558964000},"page":"1361-1367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is the adult EBMT risk score valid and relevant for hematopoietic stem cell transplantation in children acute leukemia?"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8059-3015","authenticated-orcid":false,"given":"F.","family":"Baleydier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9102-4427","authenticated-orcid":false,"given":"J. E.","family":"Galimard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gonzales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dalissier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6509-8526","authenticated-orcid":false,"given":"A.","family":"Al-Seraihy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8406-0793","authenticated-orcid":false,"given":"J.-H.","family":"Dalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8928-7049","authenticated-orcid":false,"given":"C. R. S.","family":"Uppugunduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zubarovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8818-1744","authenticated-orcid":false,"given":"M.","family":"Zecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-3654","authenticated-orcid":false,"given":"F.","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9589-4136","authenticated-orcid":false,"given":"A.","family":"Kulagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9257-900X","authenticated-orcid":false,"given":"F.","family":"Fagioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5879-0610","authenticated-orcid":false,"given":"A.","family":"Balduzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4610-0870","authenticated-orcid":false,"given":"A.","family":"Biffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9341-8104","authenticated-orcid":false,"given":"Y.","family":"Chalandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4554-0265","authenticated-orcid":false,"given":"P.","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Corbacioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1174-5799","authenticated-orcid":false,"given":"Krzysztof","family":"Kalwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of Paediatric Diseases Working Party (PDWP) of European Society for Blood and Marrow Transplantation (EBMT)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"2952_CR1","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","volume":"352","author":"A Gratwohl","year":"1998","unstructured":"Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087\u201392.","journal-title":"Lancet"},{"key":"2952_CR2","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1016\/j.bbmt.2017.07.028","volume":"23","author":"R Potdar","year":"2017","unstructured":"Potdar R, Varadi G, Fein J, Labopin M, Nagler A, Shouval R. Prognostic scoring systems in allogeneic hematopoietic stem cell transplantation: where do we stand? Biol Blood Marrow Transpl. 2017;23:1839\u201346.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2952_CR3","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/bmt.2011.110","volume":"47","author":"A Gratwohl","year":"2012","unstructured":"Gratwohl A. The EBMT risk score. Bone Marrow Transpl. 2012;47:749\u201356.","journal-title":"Bone Marrow Transpl"},{"key":"2952_CR4","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.1002\/cncr.24531","volume":"115","author":"A Gratwohl","year":"2009","unstructured":"Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 2009;115:4715\u201326.","journal-title":"Cancer"},{"key":"2952_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/sj.bmt.1705550","volume":"39","author":"M Miano","year":"2007","unstructured":"Miano M, Labopin M, Hartmann O, Angelucci E, Cornish J, Gluckman E, et al. Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 2007;39:89\u201399.","journal-title":"Bone Marrow Transpl"},{"key":"2952_CR6","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1182\/bloodadvances.2020004157","volume":"5","author":"T Takachi","year":"2021","unstructured":"Takachi T, Watanabe T, Miyamura T, Moriya Saito A, Deguchi T, Hori T, et al. Hematopoietic stem cell transplantation for infants with high-risk KMT2A gene-rearranged acute lymphoblastic leukemia. Blood Adv. 2021;5:3891\u20139.","journal-title":"Blood Adv"},{"key":"2952_CR7","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/JCO.22.02120","volume":"41","author":"RE van Weelderen","year":"2023","unstructured":"van Weelderen RE, Klein K, Harrison CJ, Jiang Y, Abrahamsson J, Arad-Cohen N, et al. Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A-rearranged acute myeloid leukemia: a study by the International Berlin-Frankfurt-M\u00fcnster Study Group. J Clin Oncol. 2023;41:2963\u201374.","journal-title":"J Clin Oncol"},{"key":"2952_CR8","doi-asserted-by":"crossref","unstructured":"Sureda A, Corbacioglu S, Greco R, Kroger N, Carreras E, editors. The EBMT handbook: hematopoietic cell transplantation and cellular therapies. 8th ed. Gewerbestrasse 11, 6330 Cham, Switzerland: Springer Nature; 2024.","DOI":"10.1007\/978-3-031-44080-9"},{"key":"2952_CR9","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1182\/bloodadvances.2018030171","volume":"3","author":"RS Mehta","year":"2019","unstructured":"Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, et al. GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood Adv. 2019;3:1441\u20139.","journal-title":"Blood Adv"},{"key":"2952_CR10","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1182\/blood.V99.6.2002","volume":"99","author":"AE Woolfrey","year":"2002","unstructured":"Woolfrey AE, Anasetti C, Storer B, Doney K, Milner LA, Sievers EL, et al. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood. 2002;99:2002\u20138.","journal-title":"Blood"},{"key":"2952_CR11","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","volume":"37","author":"C Meyer","year":"2023","unstructured":"Meyer C, Larghero P, Almeida Lopes B, Burmeister T, Groger D, Sutton R, et al. The KMT2A recombinome of acute leukemias in 2023. Leukemia. 2023;37:988\u20131005.","journal-title":"Leukemia"},{"key":"2952_CR12","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1182\/bloodadvances.2023010591","volume":"8","author":"P Bader","year":"2024","unstructured":"Bader P, Potschger U, Dalle JH, Moser LM, Balduzzi A, Ansari M, et al. Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study. Blood Adv. 2024;8:416\u201328.","journal-title":"Blood Adv"},{"key":"2952_CR13","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.bbmt.2017.04.017","volume":"23","author":"LM Vrooman","year":"2017","unstructured":"Vrooman LM, Millard HR, Brazauskas R, Majhail NS, Battiwalla M, Flowers ME, et al. Survival and late effects after allogeneic hematopoietic cell transplantation for hematologic malignancy at less than three years of age. Biol Blood Marrow Transpl. 2017;23:1327\u201334.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2952_CR14","doi-asserted-by":"crossref","unstructured":"Balduzzi A, Glogova E, Peters C, Sedlacek P, Dalle JH, Locatelli F, et al. Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM Trial. Haematologica. 2025;111:122\u201334.","DOI":"10.3324\/haematol.2025.287456"},{"key":"2952_CR15","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/bjh.12639","volume":"164","author":"A Balduzzi","year":"2014","unstructured":"Balduzzi A, Di Maio L, Silvestri D, Songia S, Bonanomi S, Rovelli A, et al. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? Br J Haematol. 2014;164:396\u2013408.","journal-title":"Br J Haematol"},{"key":"2952_CR16","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","volume":"122","author":"RB Walter","year":"2013","unstructured":"Walter RB, Buckley SA, Pagel JM, Wood BL, Storer BE, Sandmaier BM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013;122:1813\u201321.","journal-title":"Blood"},{"key":"2952_CR17","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","volume":"57","author":"JA Snowden","year":"2022","unstructured":"Snowden JA, Sanchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transpl. 2022;57:1217\u201339.","journal-title":"Bone Marrow Transpl"},{"key":"2952_CR18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/pbc.23057","volume":"57","author":"W Wood","year":"2011","unstructured":"Wood W, Deal A, Whitley J, Sharf A, Serody J, Gabriel D, et al. Usefulness of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in predicting outcomes for adolescents and young adults with hematologic malignancies undergoing allogeneic stem cell transplant. Pediatr Blood Cancer. 2011;57:499\u2013505.","journal-title":"Pediatr Blood Cancer"},{"key":"2952_CR19","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.1182\/bloodadvances.2024013484","volume":"8","author":"R Elfeky","year":"2024","unstructured":"Elfeky R, Builes N, Pearce R, Kania S, Nademi Z, Lucchini G, et al. Pediatric adapted risk index to predict 2-year transplant-related mortality post-HSCT in children. Blood Adv. 2024;8:5838\u201352.","journal-title":"Blood Adv"},{"key":"2952_CR20","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1182\/bloodadvances.2019000449","volume":"3","author":"P Bader","year":"2019","unstructured":"Bader P, Salzmann-Manrique E, Balduzzi A, Dalle JH, Woolfrey AE, Bar M, et al. More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. Blood Adv. 2019;3:3393\u2013405.","journal-title":"Blood Adv"},{"key":"2952_CR21","doi-asserted-by":"publisher","first-page":"777108","DOI":"10.3389\/fped.2021.777108","volume":"9","author":"P Merli","year":"2021","unstructured":"Merli P, Ifversen M, Truong TH, Marquart HV, Buechner J, Wolfl M, et al. Minimal residual disease prior to and after haematopoietic stem cell transplantation in children and adolescents with acute lymphoblastic leukaemia: what level of negativity is relevant? Front Pediatr. 2021;9:777108.","journal-title":"Front Pediatr"},{"key":"2952_CR22","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/14737140.2021.1860763","volume":"21","author":"WH Segerink","year":"2021","unstructured":"Segerink WH, de Haas V, Kaspers GJL. Measurable residual disease in pediatric acute myeloid leukemia: a systematic review. Expert Rev Anticancer Ther. 2021;21:451\u20139.","journal-title":"Expert Rev Anticancer Ther"},{"key":"2952_CR23","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1182\/blood.2020009342","volume":"137","author":"M Qayed","year":"2021","unstructured":"Qayed M, Ahn KW, Kitko CL, Johnson MH, Shah NN, Dvorak C, et al. A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. Blood. 2021;137:983\u201393.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02952-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02952-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02952-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:59:36Z","timestamp":1791554376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02952-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2952"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02952-8","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None of the co-authors disclose a conflict of interest related to this work. Some disclosures not related to this work are as follows: YC has received consulting fees via the institution for the advisory board from MSD, Novartis, Incyte, BMS, Pfizer, AbbVie, Roche, Jazz, Gilead, Amgen, AstraZeneca, Servier, Takeda, Pierre Fabre, Medac; Travel support from MSD, Roche, Novartis, Pfizer, BMS, Gilead, Amgen, Incyte, Abbvie, Janssen, AstraZeneca, Jazz, Pierre Fabre, Sanofi all via the institution. PB declares research grants from Neovii, Riemser, medac GmbH (to Institution); advisory board for Novartis, Cellgene, Amgen, medac (personal and to Institution); Speakers Bureau of Miltenyi, Jazz, Riemser, Novartis and Amgen (to Institution). Licensing fees and royalties from Medac. MA has received travel grants from Jazz Pharmaceuticals and Novo Nordisk and has served on the Swiss advisory board for Vertex Pharmaceuticals. JHD has received consulting fees for the advisory board from MSD, Novartis, Pfizer, Jazz, Pierre Fabre, Medac, Neovii, Sanofi, and travel support from Novartis, Sanofi, Neovii, Medac, Jazz, and Pierre Fabre.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was approved by the scientific committee of the Paediatric Diseases Working Party of EBMT. All patients and\/or their legal representatives have provided written informed consent according to local regulations to report pseudonymized data to the EBMT. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}